January 2009
Synthetic Strategy Toward 1,9-Functionalized Pyrido[2,3-d:6,5-d0]
dipyrimidine-2,4,6,8-tetrones
83
pressure to provide 17 (C43H37N5O10, 812 mg, 80%) as a
white solid. Rf ¼ 0.2 (90% ethyl acetate/hexane); mp 172.8–
173.9ꢀC; 1H NMR (500 MHz, acetone-d6) d (ppm): 9.63 (s,
2H), 8.94 (s, 1H), 7.33–7.30 (m, 10H), 6.87–6.85 (m, 8H),
5.11 (s, 4H), 3.77 (s, 12H); 13C NMR (125 MHz, acetone-d6)
d (ppm): 196.8, 161.1, 160.5, 154.8, 151.9, 142.3, 131.8,
(m, 4H), 1.75–1.69 (m, 4H), 1.57–1.45 (m, 4H); 13C NMR
(150 MHz, D2O) d (ppm): 173.1, 162.1, 154.8, 152.1, 140.2,
108.0, 62.6, 44.5, 39.3, 39.0, 29.6, 26.7, 21.8; HRMS: m/z
592.2838 (Mþ). Anal. Calcd. for C25H37N9O8ꢄ3.2CF3-
COOHꢄ0.5H2O: C, 39.06; H, 4.30; N, 13.06. Found: C, 38.66,
H, 4.69, N, 13.39.
131.4, 114.8, 108.6, 60.8, 56.1, 53.4; MS: m/z 784.6 (Mþ
þ
Acknowledgment. This work was supported by the National
Research Council of Canada, University of Alberta, Natural Sci-
ences and Engineering Research Council of Canada and the Ca-
nadian Foundation for Innovation.
1). Anal. Calcd. for C43H37N5O10: C, 65.89; H, 4.76; N, 8.94.
Found: C, 65.98, H, 4.93, N, 8.60.
1,9-Di((S)-2-(trimethylsilyl)ethyl-2-amino-6-(benzyloxy-car-
bonylamino)hexanoate)-3,7-(bis(4-methoxyphenyl)methyl)pyr-
ido[2,3-d:6,5-d0]dipyrimidine-2,4,6,8(1H,3H,7H,9H)-tetrone
(18). A solution of 17 (200 mg, 0.26 mmol) in dichloroethane
(20 mL) was treated with N-Cbz-L-Lysine-OCH2CH2TMS (250
mg, 0.65 mmol) at room temperature. After stirring for 15
min, Na(AcO)3BH (165 mg, 0.78 mmol) was added and stir-
ring was continued for an additional 48 h. The reaction was
then quenched with water and the product was extracted with
dichloromethane (2ꢂ). The combined organic layers were
washed successively with 10% aqueous citric acid, water, 5%
aqueous sodium bicarbonate and brine, dried over anhydrous
sodium sulfate. Concentration under reduced pressure followed
by purification by silica gel preparative thin layer chromatog-
raphy (90% ethyl acetate/hexane) yielded compound 18 as
white foam (C81H101N9O16Si2, 346 mg, 89%). Rf ¼ 0.8 (90%
ethyl acetate/hexane); 1H NMR (600 MHz, CD2Cl2) d (ppm):
9.02 (s, 1H), 7.34–7.29 (m, 20H), 6.85–6.84 (m, 8H), 5.03 (s,
4H), 4.98 (s, 2H), 4.35 (dt, J ¼ 13.2, 6.6 Hz, 4H), 4.16–4.13
(m, 4H), 3.77 (s, 12H), 3.15 (t, J ¼ 6.6 Hz, 2H), 3.06 (dt, J ¼
13.2, 6.6 Hz, 4H), 2.97 (dt, J ¼ 13.0, 6.0 Hz, 2H), 2.80–2.76
(m, 2H), 2.0 (broad s, 2H), 1.60–1.25 (m, 12H), 0.96–0.93 (m,
4H), 0.02 (s, 18H) 13C NMR (150 MHz, CD2Cl2) d (ppm):
175.8, 160.4, 159.6 , 156.8, 154.2, 151.4, 141.9, 137.7, 131.0,
130.9, 130.5, 128.9, 128.5, 113.9, 107.5, 66.8, 63.4, 61.7, 60.0,
55.8, 46.1, 43.6, 41.4, 33.6, 30.2, 23.6, 17.9, ꢃ1.2; MS: m/z
1512.8 (Mþ þ 1). Anal. Calcd. for C81H101N9O16Si2: C,
64.31; H, 6.73; N, 8.33. Found: C, 64.05, H, 6.78, N, 7.93.
REFERENCES AND NOTES
[1] (a) Nasr, M. N.; Gineinah, M. M. Arch. Pharm Pharm Med
Chem 2002, 6, 289; (b) Suresh, T.; Kumar, R. N.; Mohan, P. S. Heter-
ocycl Commun 2003, 9, 203.
[2] (a) Nagamatsu, T.; Yamato, H.; Ono, M.; Takarada, S.;
Yoneda, F. J Chem Soc Perkin Trans 1992, 1, 2101; (b) Yoneda, F.;
Yamato, H.; Ono, M. J Am Chem Soc 1981, 103, 5943.
[3] Petersen, P. M.; Wu, W.; Fenlon, E. E.; Kim, S.; Zimmer-
man, S. C. Bioorg Med Chem 1996, 4, 1107.
[4] (a) Traube, W. Ber 1900, 33, 3095; (b) Speer, J. H.; Ray-
mond, A. L. J Am Chem Soc 1953, 75, 114; (c) Papesch, V.;
Schroeder, E. F. J Org Chem 1951, 16, 1879; (d) Bredereck, H. Pharm
Ztg 1971, 116, 780.
[5] (a) Dabiri, M.; Arvin-Nezhad, H.; Khavasi, H. R.; Bazgir,
A. Tetrahedron 2007, 63, 1770; (b) Elderfield, R. C.; Wharmby, M. J
Org Chem 1967, 32, 1638.
[6] (a) Fenniri, H.; Deng, B.-L.; Ribbe, A. E. J Am Chem Soc
2002, 24, 11064; (b) Fenniri, H.; Deng, B.-L.; Ribbe, A. E.; Hallenga,
K.; Jacob, J.; Thiyagarajan, P. Proc Natl Acad Sci USA 2002, 99,
6487; (c) Fenniri, H.; Mathivanan, P.; Vidale, K. L.; Sherman, D. M.;
Hallenga, K.; Wood, K. V.; Stowell, J. G. J Am Chem Soc 2001, 123,
3854; (d) Moralez, J. G.; Raez, J.; Yamazaki, T.; Kishan, M. R.;
Kovalenko, A.; Fenniri, H. J Am Chem Soc 2005, 127, 8307; (e)
Raez, J.; Moralez, J. G.; Fenniri, H. J Am Chem Soc 2004, 126,
16298; (f) Johnson, R. S.; Yamazaki, T.; Kovalenko, A.; Fenniri, H. J
Am Chem Soc 2007, 129, 5735; (g) Beingessner, R. L.; Deng, B.-L.;
Fanwick, P. E.; Fenniri, H. J Org Chem 2008, 73, 931.
1,9-Di((S)-2,6-diaminohexanoic
acid)pyrido[2,3-d:6,5-
d0]dipyrimidine-2,4,6,8 (1H,3H,7H,9H)-tetrone (19). A 94:6
v/v solution of TFA:thioanisole (10 mL) was added to 18 (70
mg, 0.046 mmol) at room temperature. After stirring for 70 h,
ether (50 mL) was added and the resulting precipitate was fil-
tered, washed with ether and dried under vacuum to provide
[7] Greene, T. W.; Wuts, P. G. M. In Protective Groups in
Organic Synthesis, 3rd ed.; Wiley: New York, NY, 1999.
[8] (a) Hanson, R. W.; Law, H. D. J Chem Soc 1965, 7285; (b)
Trost, B. M.; Keinan, E. J Org Chem 1979, 44, 3451; (c) Kawabata,
T.; Kimura, Y.; Ito, Y.; Terashima, S. Tetrahedron Lett 1986, 27,
6241; (d) AbuSbeih, K.; Bleasdale, C.; Golding, B. T.; Kitson, S. L.
Tetrahedron Lett 1992, 33, 4807.
1
19 as a white solid (31 mg, 69%). H NMR (500 MHz, D2O)
d (ppm): 8.93 (s, 1H), 4.69–4.65 (m, 4H), 3.82 (t, J ¼ 6.5 Hz,
´
[9] Jonsson, D.; Unden, A. Tetrahedron Lett 2002, 43, 3125.
¨
2H), 3.58–3.44 (m, 4H), 3.01 (t, J ¼ 7.5 Hz, 4H), 2.02–1.90
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet